The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease.
作者信息
Wright Abigail C, Lin Grace A, Whittington Melanie D, McKenna Avery, Raymond Finn, Rind David M, Agboola Foluso
机构信息
Institute for Clinical and Economic Review, Boston, MA.
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA.
出版信息
J Manag Care Spec Pharm. 2024 Nov;30(11):1338-1342. doi: 10.18553/jmcp.2024.30.11.1338.
Abstract
摘要
相似文献
1
The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease.
J Manag Care Spec Pharm. 2024 Nov;30(11):1338-1342. doi: 10.18553/jmcp.2024.30.11.1338.
2
What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials.
Immunotherapy. 2023 Dec;15(18):1511-1519. doi: 10.2217/imt-2023-0136. Epub 2023 Oct 2.
3
Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials.
Expert Rev Respir Med. 2024 Aug;18(8):645-654. doi: 10.1080/17476348.2024.2389960. Epub 2024 Aug 8.
4
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC.
5
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis.
Int J Chron Obstruct Pulmon Dis. 2020 Sep 16;15:2199-2206. doi: 10.2147/COPD.S263025. eCollection 2020.
6
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.
Respir Res. 2020 Feb 10;21(1):47. doi: 10.1186/s12931-020-1307-4.
7
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.
Int J Chron Obstruct Pulmon Dis. 2023 Jul 28;18:1611-1622. doi: 10.2147/COPD.S413436. eCollection 2023.
8
Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD.
Chest. 2025 Feb;167(2):425-435. doi: 10.1016/j.chest.2024.07.168. Epub 2024 Aug 27.
9
Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
Pharm Pat Anal. 2018 Nov;7(6):249-257. doi: 10.4155/ppa-2018-0030. Epub 2019 Jan 18.
10
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy.
Int J Chron Obstruct Pulmon Dis. 2021 Apr 22;16:1137-1148. doi: 10.2147/COPD.S307160. eCollection 2021.
引用本文的文献
1
Advancing the conversation: 30 years of scholarship in managed care pharmacy.
J Manag Care Spec Pharm. 2025 Jul;31(7):617-626. doi: 10.18553/jmcp.2025.31.7.617.
本文引用的文献
1
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC.
2
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. doi: 10.1164/rccm.202301-0106PP.
3
Mortality in the United States, 2021.
NCHS Data Brief. 2022 Dec(456):1-8.
4
Interpreting Evaluating Respiratory Symptoms in COPD Diary Scores in Clinical Trials: Terminology, Methods, and Recommendations.
Chronic Obstr Pulm Dis. 2022 Oct 26;9(4):576-590. doi: 10.15326/jcopdf.2022.0307.
5
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission.
Lancet. 2022 Sep 17;400(10356):921-972. doi: 10.1016/S0140-6736(22)01273-9. Epub 2022 Sep 5.
6
Triple Therapy versus Dual or Monotherapy with Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis.
Ann Am Thorac Soc. 2020 Oct;17(10):1308-1318. doi: 10.1513/AnnalsATS.202001-023OC.
7
Symptomatic burden of COPD for patients receiving dual or triple therapy.
Int J Chron Obstruct Pulmon Dis. 2018 Apr 27;13:1365-1376. doi: 10.2147/COPD.S163717. eCollection 2018.
8
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.
Value Health. 2014 Jul;17(5):525-36. doi: 10.1016/j.jval.2014.03.1721. Epub 2014 May 14.
9
Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020.
Chest. 2015 Jan;147(1):31-45. doi: 10.1378/chest.14-0972.
10
A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
Pharmacoeconomics. 2012 Sep 1;30(9):825-40. doi: 10.2165/11591340-000000000-00000.
Zotero 插件